文献速递艾滋病与性传播感染

南非人类免疫缺陷病毒感染者的多替拉韦血浆暴露药物遗传学

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus.
PubMed 文献 · J Infect Dis · 2022-01-01

在ADVANCE试验的284名南非人类免疫缺陷病毒感染者中,分析了多替拉韦血浆暴露的药物遗传学。UGT1A1 rs887829与多替拉韦浓度-时间曲线下面积的未解释变异独立相关(P=1.8×10-4),rs887829 T/T和C/T分别使多替拉韦清除率降低25.9%和10.8%。新发现的UGT1A位点rs28899168关联需重复验证。

要点

  • UGT1A1 rs887829与多替拉韦AUC未解释变异相关(P=1.8×10-4)。
  • rs887829 T/T和C/T分别使多替拉韦清除率降低25.9%和10.8%。
  • rs28899168在校正rs887829后仍独立关联AUC未解释变异(P=.02)。

核心结论

  • 在南非,UGT1A位点的rs887829和rs28899168与多替拉韦AUC未解释变异独立相关。
  • 新发现的rs28899168关联需重复验证。
  • 本研究增进了对非洲人群多替拉韦药物遗传学的理解。

研究设计与样本

  • 研究基于南非ADVANCE试验中启动抗逆转录病毒治疗后的个体,进行全基因组基因分型及插补。
  • 使用非线性混合效应模型建立多替拉韦群体药代动力学模型。
  • 采用线性回归模型检验与多替拉韦浓度-时间曲线下面积未解释变异(AUCVAR)的关联。
  • 遗传关联可在284名个体中评估。

主要发现

  • 在先前与多替拉韦药代动力学相关的9个多态性中,与AUCVAR关联P值最低的是UGT1A1 rs887829(P=1.8×10-4),该位点也与log10胆红素相关(P=8.6×10-13)。
  • 校正rs887829后,AUCVAR与UGT1A位点的rs28899168独立相关(P=.02),也与胆红素浓度独立相关(P=7.7×10-8)。
  • 在群体药代动力学模型中,与C/C相比,rs887829 T/T和C/T分别与多替拉韦清除率降低25.9%和10.8%相关。
  • AUCVAR全基因组关联P值最低的是CAMKMT rs343942(P=2.4×10-7)。

局限性

  • 新发现的rs28899168关联需重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir is a component of preferred antiretroviral therapy (ART) regimens. We characterized the pharmacogenetics of dolutegravir exposure after ART initiation in the ADVANCE trial in South Africa. METHODS: Genome-wide genotyping followed by imputation was performed. We developed a population pharmacokinetic model for dolutegravir using nonlinear mixed-effects modeling. Linear regression models examined associations with unexplained variability in dolutegravir area under the concentration-time curve (AUCVAR). RESULTS: Genetic associations were evaluable in 284 individuals. Of 9 polymorphisms previously associated with dolutegravir pharmacokinetics, the lowest P value with AUCVAR was UGT1A1 rs887829 (P = 1.8 × 10-4), which was also associated with log10 bilirubin (P = 8.6 × 10-13). After adjusting for rs887829, AUCVAR was independently associated with rs28899168 in the UGT1A locus (P = .02), as were bilirubin concentrations (P = 7.7 × 10-8). In the population pharmacokinetic model, rs887829 T/T and C/T were associated with 25.9% and 10.8% decreases in dolutegravir clearance, respectively, compared with C/C. The lowest P value for AUCVAR genome-wide was CAMKMT rs343942 (P = 2.4 × 10-7). CONCLUSIONS: In South Africa, rs887829 and rs28899168 in the UGT1A locus were independently associated with dolutegravir AUCVAR. The novel rs28899168 association warrants replication. This study enhances understanding of dolutegravir pharmacogenetics in Africa.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cindi Z, Kawuma AN, Maartens G, et al. Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. J Infect Dis. 2022. PMID: 35512135. doi:10.1093/infdis/jiac174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。